Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01270724 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
A Phase 2 study, sponsored by Nationwide Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01270724 is a Phase 2 study that has completed, run by Nationwide Children's Hospital. The registered enrollment target is 10 participants.
The verdict
NCT01270724, a Phase 2 study, has completed, sponsored by Nationwide Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.
Interventions
- DRUG Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-08 |
| Est. Completion | 2019-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01270724
The ClinicalTrials.gov registry entry for NCT01270724 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx). is the first listed.
NCT01270724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01270724 about?
NCT01270724 is a clinical study titled "Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)". This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.
What is the current status of trial NCT01270724?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-08. Estimated completion is 2019-12-09.
What interventions are being tested in trial NCT01270724?
The interventions under investigation include: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx). (DRUG).
Who is sponsoring clinical trial NCT01270724?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.